Core Insights - The U.S. Federal Reserve cut interest rates by 25 basis points after nearly nine months, initially boosting investor sentiment, but the S&P 500 ended a three-day rally shortly after [1] - Fed Chair Jerome Powell indicated that stock valuations remain high and the future of rate cuts is uncertain, while the labor market shows signs of slowing with moderating job growth and slightly rising unemployment [2] Value Investing Focus - In the current environment, a value investing approach focusing on quality companies at reasonable prices is particularly relevant [2] - Recommended stocks for value investors include Halozyme Therapeutics, Ranger Energy Services, Buenaventura Mining Company, Affiliated Managers Group, and LATAM Airlines Group, all of which exhibit high earnings yield [3] Earnings Yield Metric - Earnings yield is calculated as (Annual Earnings per Share/Market Price) x 100, indicating the anticipated return from earnings for each dollar invested [4] - A higher earnings yield suggests a stock is underpriced compared to those with lower earnings yield, which are seen as overpriced [4] Market Comparison - Earnings yield can be compared with the 10-year Treasury yield to assess the relative attractiveness of stocks versus bonds; when the market index yield exceeds the Treasury yield, stocks may be undervalued [5] Stock Screening Criteria - A primary screening criterion is an earnings yield greater than 10%, supplemented by estimated EPS growth for the next 12 months being greater than or equal to the S&P 500 [6] - Additional criteria include an average daily volume of at least 100,000 and a current price of $5 or more [7][8] Selected Stocks - Halozyme Therapeutics (HALO) is focused on oncology treatments, with projected earnings growth of 46% and 22.5% for 2025 and 2026, respectively [9] - Ranger Energy Services (RNGR) specializes in onshore well services, with expected earnings growth of 53% and 11.3% for 2025 and 2026 [11] - Buenaventura Mining Company (BVN) anticipates earnings growth of 4.4% and 17.7% for 2025 and 2026 [12] - Affiliated Managers Group (AMG) projects earnings growth of 13% and 15% for 2025 and 2026 [13] - LATAM Airlines Group (LTM) expects earnings growth of 45% and 19% for 2025 and 2026 [14]

Industry Overview - The biotech industry has shown resilience in 2025 despite ongoing geopolitical tensions and tariff threats, with significant investments in U.S. manufacturing by major pharma and biotech companies [1] - The Zacks Biomedical and Genetics industry includes biopharmaceutical and biotechnology firms that develop innovative drugs using advanced technology [4] - The industry is currently ranked 102 by Zacks, placing it in the top 41% of over 246 Zacks industries, indicating a decent outlook driven by consistent demand for medical treatments [15] Mergers and Acquisitions - 2025 has experienced a surge in mergers and acquisitions, particularly focused on AI-driven drug discovery, as companies seek to expand their product portfolios [2][9] - Notable acquisitions include Roche's purchase of 89bio, Inc. for $3.5 billion and Novartis's acquisition of Tourmaline Bio for $1.4 billion, highlighting a trend towards portfolio expansion in response to changing market dynamics [10] Company Performance - Biotech companies such as Halozyme Therapeutics, Akero Therapeutics, Kiniska Pharmaceuticals, ANI Pharmaceuticals, and Twist BioScience are positioned to outperform the sector [3] - Halozyme Therapeutics has seen a 63.8% increase in shares year-to-date, with a Zacks Consensus Estimate for 2025 EPS rising to $6.18 [25] - Kiniska Pharmaceuticals has experienced an 82.4% share increase, with the Zacks Consensus Estimate for 2025 EPS rising to $1.03 [28] - ANI Pharmaceuticals shares have gained 73.6% this year, with earnings estimates for 2025 increasing by 84 cents [33] - Akero Therapeutics has seen a 66.8% increase in shares, focusing on treatments for metabolic diseases [36] - Twist Bioscience is expanding its technology to include synthetic RNA and antibody proteins, collaborating with Synthetic Design Lab for cancer treatments [41] Market Trends - The focus on innovation and execution is critical, with companies investing heavily in research and development to create breakthrough treatments [6] - The use of AI technology in drug discovery is expected to attract further investment in the biotech sector [11] - New drug approvals have accelerated in 2025, contributing to positive market momentum despite a challenging macro environment [11] Financial Metrics - The Zacks Biomedical and Genetics industry is trading at a trailing 12-month price-to-sales ratio of 2.16X, compared to the S&P 500's 5.95X and the Zacks Medical sector's 2.40X [20] - The industry's stock performance has gained 6% year-to-date, outperforming the Zacks Medical sector, which declined by 0.5% [17]

Core Insights - Halozyme Therapeutics (HALO) is a $9 billion biotech company focused on oncology, with sales and profit growth of 29% and 46% respectively, trading at a sub-11x forward P/E [1] - The company specializes in developing and commercializing novel treatments targeting tumor microenvironments and licenses its ENHANZE drug delivery technology for subcutaneous drug administration [1][2] Company Overview - Halozyme's ENHANZE technology is utilized by major pharmaceutical companies such as Roche, Takeda, J&J, AbbVie, Lilly, and Bristol-Myers for developing subcutaneous formulations of their marketed drugs [2] - The company currently has eight marketed partnered drugs based on the ENHANZE technology [3] Recent Developments - On May 28, Bristol Myers Squibb and Halozyme announced the European Commission's approval of a subcutaneous formulation of Opdivo for treating multiple adult solid tumors, marking it as the first PD-1 inhibitor approved for subcutaneous use in the EU [4] - Following this approval, Halozyme's stock saw significant appreciation, reaching new all-time highs above $79 [5] Market Reactions - On May 13, Morgan Stanley downgraded HALO's rating, citing potential impacts from U.S. Medicare price negotiations on HALO's drug pricing, which led to a 25% drop in stock price [6] - Despite the downgrade, profit projections for 2026 increased by 17.7%, indicating strong growth potential [7] Financial Performance - Halozyme reported a 35% year-over-year revenue increase to $265 million in Q1 2025, with royalty revenues up 39% and net income margins exceeding 43% [11] - The company maintains a high return on equity surpassing 150% and has a $250 million share repurchase program [11] Future Outlook - Analysts forecast continued growth with 11 new catalysts in approvals and indications, and the company has raised its 2025 financial guidance [12] - The average analyst price target for HALO is around $70, with a range from $51 to $91, reflecting optimism about the company's future [14]

Company Overview - Halozyme Therapeutics (HALO) currently holds a Momentum Style Score of B, indicating a favorable position in momentum investing [3] - The company has a Zacks Rank of 1 (Strong Buy), suggesting strong potential for outperformance in the market [4] Performance Metrics - Over the past week, HALO shares increased by 2.63%, while the Zacks Medical - Biomedical and Genetics industry saw a slight decline of 0.11% [6] - In a longer timeframe, HALO's monthly price change is 7.08%, outperforming the industry's 1.6% [6] - Over the past quarter, HALO shares have surged by 45.97%, and over the last year, they have gained 28.87%, compared to the S&P 500's increases of 11.2% and 19.34%, respectively [7] Trading Volume - The average 20-day trading volume for HALO is 1,750,342 shares, which serves as a bullish indicator when combined with rising stock prices [8] Earnings Outlook - In the last two months, five earnings estimates for HALO have been revised upwards, with no downward revisions, leading to an increase in the consensus estimate from $5.48 to $6.18 [10] - For the next fiscal year, five estimates have also moved upwards without any downward revisions [10] Conclusion - Considering the positive performance metrics and earnings outlook, HALO is positioned as a 1 (Strong Buy) stock with a Momentum Score of B, making it a strong candidate for near-term investment [12]

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the best affordable biotech stocks to invest in now. On August 18, Morgan Stanley raised the firm’s price target on Halozyme Therapeutics, Inc. (NASDAQ:HALO) to $80 from $75, keeping an Overweight rating on the shares. Is Halozyme Therapeutics, Inc. (HALO) the Unstoppable Growth Stock to Invest in Now? The firm told investors in a research note that the EPS 2025 guidance for Halozyme Therapeutics, Inc. (NASDAQ:HALO) has increased by 20% since January, f ...

PresentationFor this session, we have the Halozyme President and CEO, Helen Torley. Thank you for your time today. Greatly appreciate you being here. And maybe just to set the scene a little bit, if you'd like to make some opening remarks, Helen, that would be amazing.Good morning, everyone. Welcome to Morgan Stanley's Global Healthcare Conference. I'm Sean Laaman, the Head of the SMid-Cap Biotech Equity Research team here at the firm. For important disclosures, please see Morgan Stanley research disclosure ...

Halozyme Therapeutics FY Conference Summary Company Overview - **Company**: Halozyme Therapeutics (NasdaqGS: HALO) - **Industry**: Biotechnology - **Focus**: Drug delivery platforms, specifically subcutaneous drug delivery using ENHANZE® technology Key Points and Arguments Business Model and Revenue Growth - Halozyme's ENHANZE® platform allows for large volume delivery of biologics, enhancing patient convenience and treatment adherence [2][3] - Projected total revenue for the year is between $1.27 billion to $1.335 billion, with royalty revenue expected to be $825 million to $860 million, representing a year-over-year growth of 44% to 51% [3][18] - Key products driving growth include Darzalex Faspro, Phesgo, and Vyvgart Hytrulo, which have been recently launched and are showing strong market performance [3][4][18] Market Trends and Opportunities - There is a growing global trend towards subcutaneous drug delivery, particularly in markets like China, where patients prefer simpler administration methods [5][6] - The recent national reimbursement approval for Phesgo in China has led to significant growth, indicating strong market potential for subcutaneous therapies [5][6] Regulatory Environment - Positive changes in FDA regulations have streamlined the approval process for subcutaneous therapies, benefiting Halozyme and its partners [8][9] - The company is actively engaging with CMS regarding the Inflation Reduction Act (IRA) and its implications for ENHANZE® products, emphasizing the clinical benefits and cost savings associated with subcutaneous delivery [10][11][13] Financial Strategy and Capital Allocation - Halozyme has been returning capital to investors through share repurchases, totaling approximately $1.85 billion since 2019 [4][32] - The company maintains a strong cash flow with a projected adjusted EBITDA margin of 73% to 75% by 2028, allowing for continued investment in business growth and potential acquisitions [29][30] Innovation and Future Growth - Halozyme is exploring additional drug delivery platforms beyond ENHANZE®, with a focus on technologies that can enhance patient care and expand its product offerings [40][41] - The company is confident in its ability to maintain leadership in the hyaluronidase space due to its extensive experience, safety database, and established partnerships [48][49] Competitive Landscape - Halozyme's unique business model, which minimizes R&D costs while benefiting from partner success, positions it favorably against competitors in the drug delivery space [29][43] - The company is actively pursuing new partnerships and product developments, with expectations to sign additional ENHANZE® agreements in the near future [44][45] Legal Considerations - Ongoing litigation with Merck regarding patent infringement is viewed as an opportunity to protect intellectual property without risk to current revenue streams [50][51] Additional Insights - The launch of the prefilled syringe for Vyvgart Hytrulo has demonstrated the potential for expanding the prescriber base and enhancing patient convenience, which could be replicated across other products [34][36] - The company is optimistic about the long-term revenue projections, driven by the increasing adoption of subcutaneous therapies and the durability of its royalty streams [24][25][30]

Core Insights - Stock markets are reaching new records as investor confidence grows regarding potential Federal Reserve rate cuts due to a softening labor market and rising inflation from tariffs [1] Company Summaries - **Halozyme Therapeutics, Inc. (HALO)**: A biopharmaceutical company focused on oncology treatments and drug delivery technology. Expected earnings growth of 46.1% in 2025, with a 9.1% increase in broker ratings over the past four weeks. Currently holds a Zacks Rank 1 [7][8][10] - **Leidos Holdings, Inc. (LDOS)**: A global leader in science and technology serving defense, intelligence, civil, and health markets. Projected earnings growth of 9.2% in 2025, with a 5.6% increase in broker ratings over the past four weeks. Currently holds a Zacks Rank 2 [9][11][10] - **TransUnion (TRU)**: A leading provider of risk and information solutions. Expected earnings growth of 4.1% in 2025, with a 5% increase in broker ratings over the past four weeks. Currently holds a Zacks Rank 2 [11][12][10]

Core Insights - The company, Halozyme, is a pioneer in the use of hyaluronidases for large volume subcutaneous delivery, which has led to the development of its core platform, ENHANZE, licensed to major pharmaceutical companies for transforming IV drugs to subcutaneous administration [1] Group 1 - The company has achieved 10 approvals to date, indicating significant progress in its product offerings [2]

Financial Data and Key Metrics Changes - The company raised its revenue guidance for FY 2025 to $1.3 billion, with royalties from the ENHANZE® platform expected to be between $825 million and $860 million, representing a year-over-year growth of 46% to 51% [5][6] - EBITDA is projected to be at least $865 million, indicating a growth in the high 30% range [6] - The company has returned $1.8 billion to shareholders through share repurchases since 2019, including $303 million in the current year [7] Business Line Data and Key Metrics Changes - The ENHANZE® platform has achieved 10 approvals to date, with significant contributions from products launched between 2020 and 2023, including Darzalex® subcutaneous, VYVGART® Hytrulo, and Fesgo® [4][6] - VYVGART® Hytrulo has shown remarkable growth, achieving $1 billion in revenue in the second quarter, with a 100% year-over-year growth driven by its subcutaneous launch [10][11] - The company anticipates additional launches for Opdivo®, Tecentriq®, Ocrevus®, and Rybrevant®, which are expected to contribute meaningfully in 2026 and beyond [6][12] Market Data and Key Metrics Changes - The company is experiencing strong adoption of its subcutaneous delivery technology, with Darzalex® growing at 20% year-over-year and projected to reach $18 billion by 2028 [10] - Ocrevus® subcutaneous has already treated 6,500 patients worldwide, with 50% being new to the drug, indicating market expansion [17] Company Strategy and Development Direction - The company is focused on expanding its delivery platforms and exploring new partnerships, particularly in oncology, inflammation, immunology, neurology, and nephrology [23][24] - Halozyme is actively pursuing new deals and expects to sign at least one additional deal this year, which should progress into clinical trials next year [46] - The company is also looking for new drug delivery platforms that align with its revenue profiles to enhance growth [56] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about continued strong revenue growth driven by multiple catalysts, including new product approvals and market expansions [54] - The company is confident in its ability to influence policy discussions regarding the Inflation Reduction Act and its potential impact on revenue [30][31] - Management highlighted the importance of ongoing litigation with Merck, which could result in additional revenue streams if successful [37][40] Other Important Information - The company has a robust pipeline with nine products in development, including two in phase three trials, which could provide additional growth opportunities [47] - The co-formulation patent for VYVGART® Hytrulo could extend royalties until 2042, indicating a long revenue tail for the product [51] Q&A Session Summary Question: How is the long-term growth outlook for VYVGART® Hytrulo? - Management indicated that VYVGART® Hytrulo has significant growth potential, with ongoing studies to expand its indications and a strong market presence [12][11] Question: What is the launch trajectory for PD-1s like Opdivo® and Tecentriq®? - Management noted that Opdivo® is seeing good adoption, with a five-minute subcutaneous injection being attractive to physicians and patients [15][14] Question: How is the company addressing the Inflation Reduction Act? - Management is actively engaging with policy discussions and believes that the clinical benefits of their subcutaneous delivery technology will be recognized [26][30] Question: Can you provide an update on the Merck litigation? - Management confirmed that they are pursuing legal action against Merck for patent infringement and are confident in their position [36][37]